Artivion, Inc. (NYSE:AORT) CFO Sells $89,003.29 in Stock

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of Artivion stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $89,003.29. Following the sale, the chief financial officer now directly owns 75,805 shares in the company, valued at $2,070,234.55. This trade represents a 4.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Artivion Price Performance

AORT opened at $25.34 on Friday. The company has a 50-day moving average of $29.58 and a 200-day moving average of $27.80. The company has a market capitalization of $1.06 billion, a P/E ratio of -1,267.00 and a beta of 1.75. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Equities analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AORT. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Oppenheimer boosted their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $31.40.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Wasatch Advisors LP lifted its stake in Artivion by 27.7% during the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after purchasing an additional 226,160 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in Artivion during the third quarter valued at approximately $5,798,000. Point72 Asset Management L.P. acquired a new stake in Artivion during the fourth quarter valued at approximately $5,573,000. First Trust Advisors LP acquired a new stake in Artivion during the fourth quarter valued at approximately $4,771,000. Finally, Tidal Investments LLC lifted its stake in Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after purchasing an additional 134,642 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.